<SEC-DOCUMENT>0001140361-23-059159.txt : 20231222
<SEC-HEADER>0001140361-23-059159.hdr.sgml : 20231222
<ACCEPTANCE-DATETIME>20231222161531
ACCESSION NUMBER:		0001140361-23-059159
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231222
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231222
DATE AS OF CHANGE:		20231222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		231509977

	BUSINESS ADDRESS:	
		STREET 1:		ROUTE 206 AND PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543
		BUSINESS PHONE:		6092524621

	MAIL ADDRESS:	
		STREET 1:		ROUTE 206 AND PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20017313_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:bmy="http://bms.com/20231222" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_822aa5254ede4486a2f224bfb3a750c8" contextRef="c20231222to20231222" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_1eb658b9d11241d79f6be1de5e14d45b" contextRef="c20231222to20231222">0000014272</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_61f2380bbc17420bb35c19adc121a9c4" contextRef="c20231222to20231222_StatementClassOfStockAxis_CommonStockMember">NYSE</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_4e9809348b424215906b1950b7d226e4" contextRef="c20231222to20231222_StatementClassOfStockAxis_One000NotesDue2025Member">NYSE</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_2382495566e242468683c6f06c897267" contextRef="c20231222to20231222_StatementClassOfStockAxis_One750NotesDue2035Member">NYSE</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_3b6f4c9386d84711bde5b7c03865caf2" contextRef="c20231222to20231222_StatementClassOfStockAxis_CelgeneContingentValueRightsMember">NYSE</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="bmy-20231222.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20231222to20231222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000014272</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231222to20231222_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000014272</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231222to20231222_StatementClassOfStockAxis_One000NotesDue2025Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000014272</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bmy:One000NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231222to20231222_StatementClassOfStockAxis_One750NotesDue2035Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000014272</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bmy:One750NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231222to20231222_StatementClassOfStockAxis_CelgeneContingentValueRightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000014272</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bmy:CelgeneContingentValueRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div><span style="font-size: 14pt;"> </span></div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br />
    </div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 22%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div><br /></div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_0c06a44c217a411eacb2ff7dc848fdf1" contextRef="c20231222to20231222">8-K</ix:nonNumeric></div>

    <div><br /></div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 22%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 OR 15(d) of</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">The Securities Exchange Act of 1934</div>

    <div><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_00296b5e003d49208a5a4f30a3b52365" contextRef="c20231222to20231222" format="ixt:date-monthname-day-year-en">December 22, 2023</ix:nonNumeric></div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br />
    </div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 22%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_1379cd985fa245b498bfb461d1a9d2f4" contextRef="c20231222to20231222">BRISTOL-MYERS SQUIBB COMPANY</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

    <div><br /></div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 22%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div> <br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_e10b58dbad154a9e90cda225e916c9f5" contextRef="c20231222to20231222" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_79e4f245aa5a472a87dd6c2ce3d4a801" contextRef="c20231222to20231222">001-01136</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_12f35942a8ec40a3bddff7fbdec68d4f" contextRef="c20231222to20231222">22-0790350</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(State or Other Jurisdiction of Incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Commission File Number)</div>
          </td>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(IRS Employer Identification Number)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_d128ad134a504481b887bedd268ed625" contextRef="c20231222to20231222">Route 206 &amp; Province Line Road</ix:nonNumeric><br />
      <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_1c9a8c2b36454d7d89b90e604fc7fd7c" contextRef="c20231222to20231222">Princeton</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_5b10b188f5ba4956b8f652bc43164329" contextRef="c20231222to20231222" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_be6d44d820ea48a5b55fa248a9ee82af" contextRef="c20231222to20231222">08543</ix:nonNumeric></div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Address of principal executive offices) (zip code)</div>

    <div><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_c177d8df447642a9bccec53f6628d732" contextRef="c20231222to20231222">609</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_7480872499bc46da984d2d05e8735f6c" contextRef="c20231222to20231222">252-4621</ix:nonNumeric></div>

    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br />
      </div>

      <div>
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 22%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
      under any of the following provisions (see<span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#160;</span>General Instruction A.2. below):</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_bf4caf08b01e44bfb2b6161c44b5e3d8" contextRef="c20231222to20231222" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_a354568c11134774a3d8b1812d16ebfe" contextRef="c20231222to20231222" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_dc0debe292cd4c28a90ca4a51216cb36" contextRef="c20231222to20231222" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_f62707c2f4154be8a9715e774db95785" contextRef="c20231222to20231222" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.54%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 19.99%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Trading Symbol(s)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 42%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.54%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_c1d245a10ffd433a93c26fb7bd58a255" contextRef="c20231222to20231222_StatementClassOfStockAxis_CommonStockMember">Common Stock, $0.10 Par Value</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 19.99%; vertical-align: bottom; text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_d9be2d5205fb40ac90d2f3f2040a70ee" contextRef="c20231222to20231222_StatementClassOfStockAxis_CommonStockMember">BMY</ix:nonNumeric></td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 42%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_61f2380bbc17420bb35c19adc121a9c4">New York Stock Exchange</span><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.54%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_0f9c63daa83e4939b09179159e423472" contextRef="c20231222to20231222_StatementClassOfStockAxis_One000NotesDue2025Member">1.000% Notes due 2025</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 19.99%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_8ce0bb1bb0ed4ce5af79ec7d2fd2d73c" contextRef="c20231222to20231222_StatementClassOfStockAxis_One000NotesDue2025Member">BMY25</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 42%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_4e9809348b424215906b1950b7d226e4">New York Stock Exchange</span><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.54%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_7cda793d471f4530ad4de01dfefa70ae" contextRef="c20231222to20231222_StatementClassOfStockAxis_One750NotesDue2035Member">1.750% Notes due 2035</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 19.99%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_8a9f02938f7140af929e2f51316090ca" contextRef="c20231222to20231222_StatementClassOfStockAxis_One750NotesDue2035Member">BMY35</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 42%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_2382495566e242468683c6f06c897267">New York Stock Exchange</span><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.54%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_ee08fff6b35b41b3950baeafd536fd8e" contextRef="c20231222to20231222_StatementClassOfStockAxis_CelgeneContingentValueRightsMember">Celgene Contingent Value Rights</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 19.99%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_6a147f05e7284c7bb4ecea9c81efc182" contextRef="c20231222to20231222_StatementClassOfStockAxis_CelgeneContingentValueRightsMember">CELG RT</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 42%; vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_3b6f4c9386d84711bde5b7c03865caf2">New York Stock Exchange</span><br />
            </div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
      chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div><br />
    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_a741d8f7059a4aa6ba373279f398b08b" contextRef="c20231222to20231222" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div><br />
    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
      new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: 'Times New Roman'; font-size: 10pt;">&#9744;</span></div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01.</span>&#160;<span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Other Events.</span></div>

    <div>&#160;</div>

    <div style="text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On December 22, 2023, Bristol-Myers Squibb Company (&#8220;BMS&#8221;), and Karuna Therapeutics, Inc. (&#8220;Karuna&#8221;), issued a joint press release
      announcing that BMS, Karuna and Miramar Merger Sub Inc., a wholly owned subsidiary of BMS (&#8220;Merger Sub&#8221;), have signed an agreement and plan of merger (the &#8220;Merger Agreement&#8221;) providing that, on the terms and subject to the conditions set forth
      therein, Merger Sub will merge with and into Karuna, with Karuna surviving as a wholly owned subsidiary of BMS (the &#8220;Merger&#8221;). In the Merger, each share of Karuna common stock issued and outstanding immediately prior to the effective time of the
      Merger (other than certain excluded shares as described in the Merger Agreement) will automatically be converted into the right to receive $330.00 in cash, without interest, and subject to any required withholding taxes. A copy of the joint press
      release announcing the Merger is filed as Exhibit 99.1 to this report and is incorporated herein by reference.</div>

    <div>&#160;</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Additional Information and Where to Find it</div>

    <div>&#160;</div>

    <div style="text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the proposed acquisition of Karuna by BMS, Karuna intends to file a preliminary and definitive proxy statement.
      The definitive proxy statement and proxy card will be delivered to the stockholders of Karuna in advance of the special meeting relating to the proposed acquisition. This report is not a substitute for the proxy statement or any other document that
      may be filed by Karuna with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). KARUNA&#8217;S STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH
      OF BMS AND KARUNA WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES TO THE PROPOSED ACQUISITION. Investors and
      security holders will be able to obtain a free copy of the proxy statement and such other documents containing important information about BMS and Karuna, once such documents are filed with the SEC, through the website maintained by the SEC at
      www.sec.gov. BMS and Karuna make available free of charge at BMS&#8217; website at www.bms.com/investors and Karuna&#8217;s website at www.investors.karunatx.com, respectively, copies of materials they file with, or furnish to, the SEC.</div>

    <div>&#160;</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Participants in the Solicitation</div>

    <div>&#160;</div>

    <div style="text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This report does not constitute a solicitation of a proxy, an offer to purchase or a solicitation of an offer to sell any
      securities. BMS, Karuna and their respective directors, executive officers and certain employees may be deemed to be participants in the solicitation of proxies from the stockholders of Karuna in connection with the proposed acquisition. Information
      regarding BMS&#8217; directors and executive officers is contained in BMS&#8217; Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 14, 2023, and its definitive proxy statement for the 2023 annual
      meeting of stockholders, which was filed with the SEC on March 23, 2023. Information regarding Karuna&#8217;s directors and executive officers is contained in Karuna&#8217;s definitive proxy statement for the 2023 annual meeting of stockholders, which was filed
      with the SEC on April 27, 2023. To the extent holdings of BMS&#8217; or Karuna&#8217;s securities by their respective directors or executive officers have changed since the amounts set forth in such 2023 proxy statements, such changes have been or will be
      reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the identity of potential participants, and their direct or indirect interests, by
      security holdings or otherwise, will be included in the definitive proxy statement relating to the proposed acquisition when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC&#8217;s website at
      www.sec.gov, BMS&#8217; website at www.bms.com and Karuna&#8217;s website at www.karunatx.com.</div>

    <div>&#160;</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Cautionary Statement Regarding Forward-Looking Statements</div>

    <div>&#160;</div>

    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">This report contains &#8220;forward-looking statements&#8221; within the meaning
        of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the proposed acquisition of Karuna by BMS, the expected timetable for completing the
        transaction, future opportunities for the combined businesses, the expected benefits of BMS&#8217; acquisition of Karuna and the development and commercialization of Karuna&#8217;s product candidates, including the therapeutic and commercial potential of KarXT</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">and Karuna&#8217;s other technologies and products in development. These statements may be identified by
        the fact they use words such as &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will&#8221; and other words and terms of similar meaning and expression in connection with any
        discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These
        statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them,
        that are difficult to predict, may be beyond our control and could cause actual outcomes and results to differ materially from those expressed in, or implied by, the forward-looking statements. Actual results may differ materially because of
        numerous risks and uncertainties including with respect to (i) the approval of Karuna&#8217;s stockholders of the proposed acquisition, which may be delayed or may not be obtained, (ii) the risk that the expected benefits or synergies of the acquisition
        will not be realized, (iii) the risk that legal proceedings may be instituted related to the Merger Agreement, (iv) any competing offers or acquisition proposals for Karuna, (v) the possibility that various conditions to the consummation of the
        acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed acquisition,
        including the response of business partners and competitors to the announcement of the proposed acquisition or difficulties in employee retention as a result of the announcement and pendency of the proposed acquisition. The actual financial impact
        of this transaction may differ from the expected financial impact described in this report. In addition, the compounds described in this report are subject to all the risks inherent in the drug development process, and there can be no assurance
        that the development of these compounds will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this report should be evaluated together with the many risks and uncertainties that affect BMS&#8217;
        business and market, particularly those identified in the cautionary statement and risk factors discussion in BMS&#8217; Annual Report on Form 10-K for the year ended December 31, 2022, and Karuna&#8217;s business, particularly those identified in the risk
        factors discussion in Karuna&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other documents that may be filed by BMS or Karuna from time to time with the SEC. Neither BMS nor Karuna undertakes any obligation to
        publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. The forward-looking statements made in this report relate only to events as of the date on
        which the statements are made and readers are cautioned not to place undue reliance on such statements.</span></div>

    <div>&#160;</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</span>&#160;<span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</span></div>

    <div>&#160;</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits</div>

    <div>&#160;</div>

    <div style="text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following exhibits are included as part of this Current Report on Form 8-K:</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10.16%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10.16%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">99.1</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Joint Press Release of Bristol-Myers Squibb Company and Karuna Therapeutics, Inc., dated December 22, 2023.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10.16%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">104</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).</div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXHIBIT INDEX</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10.16%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10.16%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="ef20017313_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Joint Press Release of Bristol-Myers Squibb Company and Karuna Therapeutics, Inc., dated December 22, 2023.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10.16%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">104</div>
          </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 89%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).</div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be
      signed on its behalf by the undersigned hereunto duly authorized.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 40%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">BRISTOL-MYERS SQUIBB COMPANY</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Dated: December 22, 2023</div>
          </td>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">/s/ Kimberly M. Jablonski</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
          </td>

    <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Kimberly M. Jablonski</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Title:</div>
          </td>

    <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Corporate Secretary</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div><br />
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /> </div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20017313_ex99-1.htm
<DESCRIPTION>JOINT PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY AND KARUNA THERAPEUTICS, INC.
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer&#8217;s Disease
      Psychosis, with Promise in Additional Neuropsychiatric and Neurodegenerative Indications</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024</div>
    <div><br>
    </div>
    <div style="text-align: center; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PRINCETON, N.J. &amp; BOSTON, M.A. &#8211; December 22, 2023 &#8211;</font> Bristol Myers Squibb
      (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (&#8220;Karuna&#8221;) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total
      equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Karuna is a biopharmaceutical company driven to discover, develop and deliver transformative medicines for people living with psychiatric and neurological conditions.
      Karuna&#8217;s lead asset, KarXT (xanomeline-trospium), is an antipsychotic with a novel mechanism of action (MoA) and differentiated efficacy and safety. Karuna&#8217;s New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults was
      accepted for review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. KarXT is also in registrational trials both for adjunctive therapy to existing standard of care agents in
      schizophrenia and for the treatment of psychosis in patients with Alzheimer&#8217;s disease. Bristol Myers Squibb believes KarXT represents a significant revenue contribution opportunity. Bristol Myers Squibb also sees potential from Karuna&#8217;s early-stage
      and pre-clinical pipeline.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space. We
      expect KarXT to enhance our growth through the late 2020s and into the next decade,&#8221; said Christopher Boerner, Ph.D., Chief Executive Officer of Bristol Myers Squibb. &#8220;This transaction fits squarely within our business development priorities of
      pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need. We look forward to welcoming the talented Karuna team to Bristol Myers Squibb.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Schizophrenia and Alzheimer&#8217;s disease psychosis affect millions of people worldwide, with limited to no treatment options. KarXT&#8217;s novel mechanism has resulted in a
      transformational profile in schizophrenia, with compelling efficacy and a differentiated safety profile,&#8221; said Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb. &#8220;KarXT also has the
      potential to deliver meaningful benefits to patients as an adjunctive treatment for patients with schizophrenia and as a first treatment for Alzheimer&#8217;s disease psychosis.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Bill Meury, President and Chief Executive Officer of Karuna Therapeutics, said, &#8220;Karuna&#8217;s portfolio offers advancements in treatment not seen in many years. With Bristol
      Myers Squibb&#8217;s long-standing expertise in developing and commercializing medicines on a global scale and legacy in neuroscience, KarXT and the other assets in our pipeline will be well-positioned to reach those living with schizophrenia and
      Alzheimer&#8217;s disease psychosis. This announcement is a testament to the Karuna team&#8217;s talent, hard work, and innovation.&#8221;</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Delivering Meaningful Benefits to Patients with KarXT</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. KarXT has demonstrated improvements in cognition and is
      not associated with common side effects of currently approved treatments, including no meaningful weight gain, extrapyramidal symptoms, increased prolactin levels, akathisia and/or sedation.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Given this differentiated profile, KarXT has meaningful and expanding revenue potential in schizophrenia and with upside in additional indications and geographies:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z78f16513abee428ba312194141a03374" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Schizophrenia: </font>KarXT is expected to launch in late 2024 in the U.S. as a treatment for
              schizophrenia in adults. There are approximately 1.6 million<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> people treated for schizophrenia in the U.S., a significant portion of whom do not respond to currently available therapies and experience unacceptable side effects.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z008e70c42d9a4d4d8d461f4072f73756" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Adjunctive schizophrenia:</font> A registrational clinical trial is currently underway evaluating
              KarXT as adjunctive treatment with current standard of care agents for the treatment of schizophrenia, with data expected in 2025.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: left;"><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zd479087158bc45ddb892d469cc87df1a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Alzheimer&#8217;s disease psychosis:</font> Registrational clinical trials are currently underway
              evaluating KarXT for the treatment of Alzheimer&#8217;s disease psychosis, with data expected in 2026. There are more than 6 million<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> people living with Alzheimer&#8217;s disease in the U.S. There are currently no approved treatments for
              Alzheimer&#8217;s disease psychosis.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z1c17da2b115442f29127b7c6330411b7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional indications:</font> Bristol Myers Squibb believes KarXT also has potential in additional
              indications, including Bipolar I disorder, which impacts approximately 1.4 million<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> people in the U.S., and Alzheimer&#8217;s disease agitation.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The transaction is expected to be dilutive to Bristol Myers Squibb&#8217;s non-GAAP diluted earnings per share by approximately $0.30 in 2024 from the financing cost of the
      transaction, as Bristol Myers Squibb expects to offset the operational expenses of the transaction through continued resource allocation, cost efficiencies and portfolio prioritization. The accounting treatment as a business combination or asset
      acquisition will be determined upon the expected close of the transaction. Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance. Bristol Myers Squibb&#8217;s cash flows and strong financial profile enable continued
      commitment to strong investment-grade credit ratings and investment for growth through business development opportunities and distributions to shareholders through ongoing dividends and share repurchases.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Transaction Terms and Financing</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the merger agreement, Bristol Myers Squibb will acquire all outstanding shares of Karuna common stock for $330.00 per share in cash representing an
      approximately 53.4% premium to Karuna Therapeutic&#8217;s closing stock price on December 21, 2023, for a total equity value of approximately $14.0 billion, or $12.7 billion net of estimated cash acquired.<br>
      <br>
    </div>
    <div>
      <hr noshade="noshade" align="left" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto 0px 0px; height: 2px; width: 25%; color: #000000; text-align: left;"> </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Source: DRG &#8211; Clarivate, as of July 2023.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Source: &#8220;Alzheimer&#8217;s Disease Association Facts and Figures,&#8221; 2023.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including approval of Karuna stockholders and receipt of required
      regulatory approvals.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Conference Call Information</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET during which company executives will review discuss the transaction and
      address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at <u>http://investor.bms.com</u>.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Investors and the public can register for the live conference call <u>here</u>. Those unable to register can access the live conference call by dialing in the U.S.
      toll-free 1-866-777-2509 or international +1 412-317-5413. Materials related to the call will be available at <u>http://investor.bms.com</u> prior to the start of the conference call.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">A replay of the webcast will be available at <u>http://investor.bms.com</u> approximately three hours after the conference call concludes. A replay of the conference call
      will be available beginning at 11:30 a.m. ET on December 22, 2023, through 11:30 a.m. ET on January 4, 2024, by dialing in the U.S. toll free 1-877-344-7529 or international +1 412-317-0088, confirmation code: 3194180.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Advisors</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Gordon Dyal &amp; Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington &amp; Burling LLP is serving as legal counsel. Goldman Sachs &amp;
      Co. LLC is serving as exclusive financial advisor to Karuna, and Simpson Thacher &amp; Bartlett LLP is serving as legal counsel.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Bristol Myers Squibb</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious
      diseases. For more information about Bristol Myers Squibb, visit us at <u>BMS.com</u> or follow us on <u>LinkedIn</u>, <u>Twitter</u>, <u>YouTube</u>, <u>Facebook</u>, and <u>Instagram</u>.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Karuna Therapeutics</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Karuna Therapeutics is a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological
      conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are
      harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples&#8217; lives. For more information, please visit <u>www.karunatx.com</u>.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Additional Information and Where to Find It</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb, Karuna Therapeutics intends to file a preliminary and definitive proxy
      statement. The definitive proxy statement and proxy card will be delivered to the stockholders of Karuna Therapeutics in advance of the special meeting relating to the proposed acquisition. This press release is not a substitute for the proxy
      statement or any other document that may be filed by Karuna Therapeutics with the SEC. KARUNA THERAPEUTICS&#8217; STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS
      FILED BY EACH OF BRISTOL MYERS SQUIBB AND KARUNA THERAPEUTICS WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES
      TO THE PROPOSED ACQUISITION. Investors and security holders will be able to obtain a free copy of the proxy statement and such other documents containing important information about Bristol Myers Squibb and Karuna Therapeutics, once such documents
      are filed with the SEC, through the website maintained by the SEC at www.sec.gov. Bristol Myers Squibb and Karuna Therapeutics make available free of charge at Bristol Myers Squibb&#8217;s website at www.bms.com/investors and Karuna Therapeutics&#8217; website
      at<font style="font-family: 'Times New Roman'; font-size: 10pt;"><u>&#160;</u></font>https://karunatx.com/, respectively, copies of materials they file with, or furnish to, the SEC.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Participants in the Solicitation</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release does not constitute a solicitation of a proxy, an offer to purchase or a solicitation of an offer to sell any securities. Bristol Myers Squibb, Karuna
      Therapeutics and their respective directors, executive officers and certain employees may be deemed to be participants in the solicitation of proxies from the stockholders of Karuna Therapeutics in connection with the proposed acquisition.
      Information regarding Bristol Myers Squibb&#8217;s directors and executive officers is contained in Bristol Myer Squibb&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 14, 2023, and its
      definitive proxy statement for the 2023 annual meeting of stockholders, which was filed with the SEC on March 23, 2023. Information regarding Karuna Therapeutics&#8217; directors and executive officers is contained in Karuna Therapeutics&#8217; definitive proxy
      statement for the 2023 annual meeting of stockholders, which was filed with the SEC on April 27, 2023. To the extent holdings of Bristol Myers Squibb&#8217;s or Karuna Therapeutics&#8217; securities by their respective directors or executive officers have
      changed since the amounts set forth in such 2023 proxy statements, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Additional
      information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be included in the definitive proxy statement relating to the proposed acquisition when it is filed with the
      SEC. These documents (when available) may be obtained free of charge from the SEC&#8217;s website at www.sec.gov, Bristol Myers Squibb&#8217;s website at www.bms.com and Karuna Therapeutics&#8217; website at https://karunatx.com/.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Cautionary Statement Regarding Forward-Looking Statements</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
      Exchange Act of 1934, as amended, regarding, among other things, the proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb, the expected timetable for completing the transaction, future opportunities for the combined businesses, the
      expected benefits of Bristol Myers Squibb&#8217;s acquisition of Karuna Therapeutics and the development and commercialization of Karuna Therapeutics&#8217; product candidates, including the therapeutic and commercial potential of KarXT and Karuna Therapeutics&#8217;
      other technologies and products in development. These statements may be identified by the fact they use words such as &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will&#8221;
      and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of
      historical facts are, or may be deemed to be, forward-looking statements. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks, assumptions and uncertainties,
      including internal or external factors that could delay, divert or change any of them, that are difficult to predict, may be beyond our control and could cause actual outcomes and results to differ materially from those expressed in, or implied by,
      the forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the approval of Karuna Therapeutics&#8217; stockholders of the proposed acquisition, which may be delayed or may
      not be obtained, (ii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iii) the risk that legal proceedings may be instituted related to the merger agreement, (iv) any competing offers or acquisition
      proposals for Karuna Therapeutics, (v) the possibility that various conditions to the consummation of the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the
      acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed acquisition, including the response of business partners and competitors to the announcement of the proposed acquisition or difficulties in employee retention
      as a result of the announcement and pendency of the proposed acquisition. The actual financial impact of this transaction may differ from the expected financial impact described in this press release. In addition, the compounds described in this
      press release are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. No forward-looking statement can be guaranteed.
      Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb&#8217;s business and market, particularly those identified in the cautionary statement and risk factors
      discussion in Bristol Myers Squibb&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, and Karuna Therapeutics&#8217; business, particularly those identified in the risk factors discussion in Karuna Therapeutics&#8217; Annual Report on Form 10-K
      for the year ended December 31, 2022, as well as other documents that may be filed by Bristol Myers Squibb or Karuna Therapeutics from time to time with the SEC. Neither Bristol Myers Squibb nor Karuna Therapeutics undertakes any obligation to
      publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. The forward-looking statements made in this press release relate only to events as of the date on
      which the statements are made and readers are cautioned not to place undue reliance on such statements.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Use of Non-GAAP Financial Information and Financial Guidance</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP).
      The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this communication that are calculated and presented in accordance with GAAP and are presented because management has evaluated the
      company&#8217;s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company&#8217;s baseline
      performance, supplement or enhance management, analysts and investors overall understanding of the company&#8217;s underlying financial performance and trends and facilitate comparisons among current, past and future periods.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an
      individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a
      particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because Bristol Myers Squibb believes they neither relate to the ordinary course of Bristol Myers
      Squibb&#8217;s business nor reflect Bristol Myers Squibb&#8217;s underlying business performance. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to or as a substitute for the related financial
        measures that are prepared in accordance with GAAP and are not intended to be considered in isolation and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in
        the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of the forward-looking non-GAAP measures presented in this communication is not provided due to the inherent difficulty in forecasting and quantifying
      items that are necessary for such reconciliation. Namely, we are not able to reliably predict the impact of specified items such as unwind of inventory purchase price adjustments, accelerated depreciation and impairment of property, plant and
      equipment and intangible assets and stock compensation resulting from acquisition-related equity awards, or currency exchange rates beyond the next twelve months. As a result, the reconciliation of these non-GAAP measures to the most directly
      comparable GAAP measures is not available without unreasonable effort. In addition, Bristol Myers Squibb believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the
      specified items may have a significant and unpredictable impact on our future GAAP results. In addition, the non-GAAP financial guidance in this communication excludes the impact of any potential additional future strategic acquisitions and
      divestitures and any specified items that have not yet been identified and quantified. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Contacts</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Bristol Myers Squibb</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Media Inquiries:</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Media: <u>media@bms.com</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investors:</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Investor Relations: <u>investor.relations@bms.com</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Karuna Therapeutics</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investors:</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Alexis Smith</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">+1 (617) 352-9917</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>asmith@karunatx.com</u></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bmy-20231222.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<xs:schema targetNamespace="http://bms.com/20231222" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:bmy="http://bms.com/20231222" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmy-20231222_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bmy-20231222_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bmy-20231222_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://bms.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:element name="One000NotesDue2025Member" id="bmy_One000NotesDue2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="One750NotesDue2035Member" id="bmy_One750NotesDue2035Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CelgeneContingentValueRightsMember" id="bmy_CelgeneContingentValueRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>bmy-20231222_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://bms.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="bmy-20231222.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://bms.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="definition: EntityListingsLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="definition: EntityListingsLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: EntityListingsLineItems to DocumentPeriodEndDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalYearFocus" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="definition: EntityListingsLineItems to EntityFileNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: EntityListingsLineItems to EntityRegistrantName" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: EntityListingsLineItems to EntityCentralIndexKey" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: EntityListingsLineItems to EntityTaxIdentificationNumber" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine2" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine3" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: EntityListingsLineItems to EntityAddressCityOrTown" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: EntityListingsLineItems to EntityAddressStateOrProvince" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="definition: EntityListingsLineItems to EntityAddressCountry" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: EntityListingsLineItems to EntityAddressPostalZipCode" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="definition: EntityListingsLineItems to CityAreaCode" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: EntityListingsLineItems to LocalPhoneNumber" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="definition: EntityListingsLineItems to Security12bTitle" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="definition: EntityListingsLineItems to TradingSymbol" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="definition: EntityListingsLineItems to NoTradingSymbolFlag" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: EntityListingsLineItems to SecurityExchangeName" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: EntityListingsLineItems to EntityEmergingGrowthCompany" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="definition: EntityListingsLineItems to WrittenCommunications" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="definition: EntityListingsLineItems to SolicitingMaterial" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementTenderOffer" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityListingsLineItems" xlink:to="EntityListingsTable" xlink:title="definition: EntityListingsLineItems to EntityListingsTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EntityListingsTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_One000NotesDue2025Member" xlink:label="One000NotesDue2025Member" xlink:title="One000NotesDue2025Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="One000NotesDue2025Member" xlink:title="definition: ClassOfStockDomain to One000NotesDue2025Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_One750NotesDue2035Member" xlink:label="One750NotesDue2035Member" xlink:title="One750NotesDue2035Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="One750NotesDue2035Member" xlink:title="definition: ClassOfStockDomain to One750NotesDue2035Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_CelgeneContingentValueRightsMember" xlink:label="CelgeneContingentValueRightsMember" xlink:title="CelgeneContingentValueRightsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CelgeneContingentValueRightsMember" xlink:title="definition: ClassOfStockDomain to CelgeneContingentValueRightsMember" order="4.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>bmy-20231222_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsTable_lbl" xml:lang="en-US" id="dei_EntityListingsTable_lbl">Entity Listings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsTable" xlink:to="dei_EntityListingsTable_lbl" xlink:title="label: EntityListingsTable to dei_EntityListingsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsLineItems_lbl" xml:lang="en-US" id="dei_EntityListingsLineItems_lbl">Entity Listings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:title="label: EntityListingsLineItems to dei_EntityListingsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_One000NotesDue2025Member" xlink:label="One000NotesDue2025Member" xlink:title="One000NotesDue2025Member" />
    <link:label xlink:type="resource" xlink:label="bmy_One000NotesDue2025Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="bmy_One000NotesDue2025Member_lbl1" xml:lang="en-US" id="bmy_One000NotesDue2025Member_lbl1">1.000% Notes due 2025 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="One000NotesDue2025Member" xlink:to="bmy_One000NotesDue2025Member_lbl1" xlink:title="label: One000NotesDue2025Member to bmy_One000NotesDue2025Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_One750NotesDue2035Member" xlink:label="One750NotesDue2035Member" xlink:title="One750NotesDue2035Member" />
    <link:label xlink:type="resource" xlink:label="bmy_One750NotesDue2035Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="bmy_One750NotesDue2035Member_lbl1" xml:lang="en-US" id="bmy_One750NotesDue2035Member_lbl1">1.750% Notes due 2035 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="One750NotesDue2035Member" xlink:to="bmy_One750NotesDue2035Member_lbl1" xlink:title="label: One750NotesDue2035Member to bmy_One750NotesDue2035Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_CelgeneContingentValueRightsMember" xlink:label="CelgeneContingentValueRightsMember" xlink:title="CelgeneContingentValueRightsMember" />
    <link:label xlink:type="resource" xlink:label="bmy_CelgeneContingentValueRightsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="bmy_CelgeneContingentValueRightsMember_lbl1" xml:lang="en-US" id="bmy_CelgeneContingentValueRightsMember_lbl1">Celgene Contingent Value Rights [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CelgeneContingentValueRightsMember" xlink:to="bmy_CelgeneContingentValueRightsMember_lbl1" xlink:title="label: CelgeneContingentValueRightsMember to bmy_CelgeneContingentValueRightsMember_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bmy-20231222_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://bms.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="bmy-20231222.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://bms.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_One000NotesDue2025Member" xlink:label="One000NotesDue2025Member" xlink:title="One000NotesDue2025Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="One000NotesDue2025Member" xlink:title="presentation: ClassOfStockDomain to One000NotesDue2025Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_One750NotesDue2035Member" xlink:label="One750NotesDue2035Member" xlink:title="One750NotesDue2035Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="One750NotesDue2035Member" xlink:title="presentation: ClassOfStockDomain to One750NotesDue2035Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="bmy-20231222.xsd#bmy_CelgeneContingentValueRightsMember" xlink:label="CelgeneContingentValueRightsMember" xlink:title="CelgeneContingentValueRightsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CelgeneContingentValueRightsMember" xlink:title="presentation: ClassOfStockDomain to CelgeneContingentValueRightsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EntityListingsTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="presentation: EntityListingsLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: EntityListingsLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: EntityListingsLineItems to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: EntityListingsLineItems to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: EntityListingsLineItems to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: EntityListingsLineItems to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: EntityListingsLineItems to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: EntityListingsLineItems to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: EntityListingsLineItems to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="presentation: EntityListingsLineItems to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: EntityListingsLineItems to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="presentation: EntityListingsLineItems to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: EntityListingsLineItems to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="presentation: EntityListingsLineItems to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="presentation: EntityListingsLineItems to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: EntityListingsLineItems to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: EntityListingsLineItems to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: EntityListingsLineItems to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="presentation: EntityListingsLineItems to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="presentation: EntityListingsLineItems to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="EntityListingsLineItems" xlink:title="presentation: EntityListingsTable to EntityListingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityListingsTable" xlink:title="presentation: CoverAbstract to EntityListingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139989903372384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 22,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-01136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BRISTOL-MYERS SQUIBB COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000014272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-0790350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Route 206 & Province Line Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">252-4621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.10 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bmy_One000NotesDue2025Member', window );">1.000% Notes due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMY25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bmy_One750NotesDue2035Member', window );">1.750% Notes due 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.750% Notes due 2035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMY35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bmy_CelgeneContingentValueRightsMember', window );">Celgene Contingent Value Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Celgene Contingent Value Rights<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELG RT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bmy_One000NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bmy_One000NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bmy_One750NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bmy_One750NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bmy_CelgeneContingentValueRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bmy_CelgeneContingentValueRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>ef20017313_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bmy="http://bms.com/20231222"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bmy-20231222.xsd" xlink:type="simple"/>
    <context id="c20231222to20231222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000014272</identifier>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="c20231222to20231222_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000014272</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="c20231222to20231222_StatementClassOfStockAxis_One000NotesDue2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000014272</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bmy:One000NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="c20231222to20231222_StatementClassOfStockAxis_One750NotesDue2035Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000014272</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bmy:One750NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="c20231222to20231222_StatementClassOfStockAxis_CelgeneContingentValueRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000014272</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bmy:CelgeneContingentValueRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20231222to20231222"
      id="Fact_822aa5254ede4486a2f224bfb3a750c8">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20231222to20231222"
      id="Fact_1eb658b9d11241d79f6be1de5e14d45b">0000014272</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20231222to20231222_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_61f2380bbc17420bb35c19adc121a9c4">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="c20231222to20231222_StatementClassOfStockAxis_One000NotesDue2025Member"
      id="Fact_4e9809348b424215906b1950b7d226e4">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="c20231222to20231222_StatementClassOfStockAxis_One750NotesDue2035Member"
      id="Fact_2382495566e242468683c6f06c897267">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="c20231222to20231222_StatementClassOfStockAxis_CelgeneContingentValueRightsMember"
      id="Fact_3b6f4c9386d84711bde5b7c03865caf2">NYSE</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20231222to20231222"
      id="Fact_0c06a44c217a411eacb2ff7dc848fdf1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20231222to20231222"
      id="Fact_00296b5e003d49208a5a4f30a3b52365">2023-12-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20231222to20231222"
      id="Fact_1379cd985fa245b498bfb461d1a9d2f4">BRISTOL-MYERS SQUIBB COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20231222to20231222"
      id="Fact_e10b58dbad154a9e90cda225e916c9f5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20231222to20231222"
      id="Fact_79e4f245aa5a472a87dd6c2ce3d4a801">001-01136</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20231222to20231222"
      id="Fact_12f35942a8ec40a3bddff7fbdec68d4f">22-0790350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20231222to20231222"
      id="Fact_d128ad134a504481b887bedd268ed625">Route 206 &amp; Province Line Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20231222to20231222"
      id="Fact_1c9a8c2b36454d7d89b90e604fc7fd7c">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20231222to20231222"
      id="Fact_5b10b188f5ba4956b8f652bc43164329">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20231222to20231222"
      id="Fact_be6d44d820ea48a5b55fa248a9ee82af">08543</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20231222to20231222"
      id="Fact_c177d8df447642a9bccec53f6628d732">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20231222to20231222"
      id="Fact_7480872499bc46da984d2d05e8735f6c">252-4621</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20231222to20231222"
      id="Fact_bf4caf08b01e44bfb2b6161c44b5e3d8">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20231222to20231222"
      id="Fact_a354568c11134774a3d8b1812d16ebfe">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20231222to20231222"
      id="Fact_dc0debe292cd4c28a90ca4a51216cb36">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20231222to20231222"
      id="Fact_f62707c2f4154be8a9715e774db95785">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20231222to20231222_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_c1d245a10ffd433a93c26fb7bd58a255">Common Stock, $0.10 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231222to20231222_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_d9be2d5205fb40ac90d2f3f2040a70ee">BMY</dei:TradingSymbol>
    <dei:Security12bTitle
      contextRef="c20231222to20231222_StatementClassOfStockAxis_One000NotesDue2025Member"
      id="Fact_0f9c63daa83e4939b09179159e423472">1.000% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231222to20231222_StatementClassOfStockAxis_One000NotesDue2025Member"
      id="Fact_8ce0bb1bb0ed4ce5af79ec7d2fd2d73c">BMY25</dei:TradingSymbol>
    <dei:Security12bTitle
      contextRef="c20231222to20231222_StatementClassOfStockAxis_One750NotesDue2035Member"
      id="Fact_7cda793d471f4530ad4de01dfefa70ae">1.750% Notes due 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231222to20231222_StatementClassOfStockAxis_One750NotesDue2035Member"
      id="Fact_8a9f02938f7140af929e2f51316090ca">BMY35</dei:TradingSymbol>
    <dei:Security12bTitle
      contextRef="c20231222to20231222_StatementClassOfStockAxis_CelgeneContingentValueRightsMember"
      id="Fact_ee08fff6b35b41b3950baeafd536fd8e">Celgene Contingent Value Rights</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231222to20231222_StatementClassOfStockAxis_CelgeneContingentValueRightsMember"
      id="Fact_6a147f05e7284c7bb4ecea9c81efc182">CELG RT</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20231222to20231222"
      id="Fact_a741d8f7059a4aa6ba373279f398b08b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M])=P95H^!Z.2$->\_@M#LSX1X(W^)5I/* UE_4\R75LK#D7_H%''^G-@O2/
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #O@997'#AEZC\!   \ @  #P
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M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ [X&65R0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( .^!EE=ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #O@9972I*HCNT    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #O@997
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( .^!EE=?L>B-< 4  'L;   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #O@997
MGZ ;\+$"  #B#   #0              @ &R#0  >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( .^!EE>7BKL<P    !,"   +              "  8X0  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( .^!EE<<.&7J/P$  #P"   /
M      "  7<1  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #O@997)!Z;
MHJT   #X 0  &@              @ 'C$@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #O@99799!YDAD!  #/ P  $P
M    @ '($P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   2
%%0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>5</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>4</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20017313_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bms.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bmy-20231222.xsd</File>
    <File>bmy-20231222_def.xml</File>
    <File>bmy-20231222_lab.xml</File>
    <File>bmy-20231222_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20017313_8k.htm">ef20017313_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20017313_8k.htm": {
   "nsprefix": "bmy",
   "nsuri": "http://bms.com/20231222",
   "dts": {
    "schema": {
     "local": [
      "bmy-20231222.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "bmy-20231222_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bmy-20231222_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmy-20231222_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ef20017313_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 3,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 5,
   "entityCount": 1,
   "segmentCount": 4,
   "elementCount": 37,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 31
   },
   "report": {
    "R1": {
     "role": "http://bms.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20231222to20231222",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20017313_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231222to20231222",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20017313_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "bmy_CelgeneContingentValueRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bms.com/20231222",
     "localname": "CelgeneContingentValueRightsMember",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Celgene Contingent Value Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "bmy_One000NotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bms.com/20231222",
     "localname": "One000NotesDue2025Member",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.000% Notes due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "bmy_One750NotesDue2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bms.com/20231222",
     "localname": "One750NotesDue2035Member",
     "presentation": [
      "http://bms.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.750% Notes due 2035 [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-23-059159-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-059159-xbrl.zip
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M<M B0+4!)HDU8?#MJQ8N%PO*8%;]=Q,E> I6@D$GU &H:UT%@*O;&M!W8*X
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M&$D"XF$:P>4?<*55WX IR5_!^*^_G=:6!J@$$PYXY[T#AFF(R1R3G&F^I3+
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MJ1-3XSO_;L)U"__!O\OOX_]02P,$%     @ [X&65W36BSP@'P  :K8  !$
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MLPQPF;:KM3W=M36OPPRCS>]%^FG,@=,G2<ZS=S,.!>S'Z %PWK!<VVZW.?3
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MB9K'<YYF9/2?6>AY1+EWQ#>.86BO#X]'XDE__:H!SH21CS2=Q92< Q/HE,\
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MV?=OW<%1]_"H+QKJGGPAIU#CD+P[[7W""D;D_> (FCO\0OK=WH>"):?OA9O
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MB^"X%&48/10E*=RH"[4(HP$MJZ:1:#EZ&SPGH.1YC-O$>-E^K=F*#2*X4NT
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M.M:!N%:!2O,D$\-I$@/8.@R%8SV9* !8KHFB1Y.)#F2P%#(.Q8V<J'SYI*!
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M3:0R,B80(XH6L5%13_P P($EBQL9S R_[) 2UW=V=M1X7WT$W#;(PE;66)K
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M]7"P=4PKH-!>6G&^<W6TYF##."Y O[M6*-+0D0 6R1R0J/N35\\F&FOPJ1&
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M2P$"% ,4    " #O@997:API8"P'   :2   %               @ $*!
M8FUY+3(P,C,Q,C(R7V1E9BYX;6Q02P$"% ,4    " #O@997A%>D Y,*  "P
M;P  %               @ %H"P  8FUY+3(P,C,Q,C(R7VQA8BYX;6Q02P$"
M% ,4    " #O@997_^MEDCH'   740  %               @ $M%@  8FUY
M+3(P,C,Q,C(R7W!R92YX;6Q02P$"% ,4    " #O@997=-:+/" ?  !JM@
M$0              @ &9'0  968R,# Q-S,Q,U\X:RYH=&U02P$"% ,4
M" #O@9970WN@0?HB  #]B@  %0              @ 'H/   968R,# Q-S,Q
B,U]E>#DY+3$N:'1M4$L%!@     &  8 A@$  !5@      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
